Mylan N.V. Company Profile (NASDAQ:MYL)

About Mylan N.V. (NASDAQ:MYL)

Mylan N.V. logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MYL
  • CUSIP: 62853010
  • Web:
  • Market Cap: $16.83385 billion
  • Outstanding Shares: 536,281,000
Average Prices:
  • 50 Day Moving Avg: $31.89
  • 200 Day Moving Avg: $37.29
  • 52 Week Range: $29.39 - $45.87
  • Trailing P/E Ratio: 25.04
  • Foreward P/E Ratio: 6.13
  • P/E Growth: 1.43
Sales & Book Value:
  • Annual Revenue: $12.01 billion
  • Price / Sales: 1.40
  • Book Value: $23.94 per share
  • Price / Book: 1.31
  • EBIDTA: $3.92 billion
  • Net Margins: 5.51%
  • Return on Equity: 22.42%
  • Return on Assets: 7.54%
  • Debt-to-Equity Ratio: 1.20%
  • Current Ratio: 1.35%
  • Quick Ratio: 0.84%
  • Average Volume: 6.43 million shs.
  • Beta: 1.31
  • Short Ratio: 6.64

Frequently Asked Questions for Mylan N.V. (NASDAQ:MYL)

What is Mylan N.V.'s stock symbol?

Mylan N.V. trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan N.V.'s earnings last quarter?

Mylan N.V. (NASDAQ:MYL) posted its earnings results on Wednesday, August, 9th. The company reported $1.10 earnings per share for the quarter, missing analysts' consensus estimates of $1.18 by $0.08. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm's revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.16 earnings per share. View Mylan N.V.'s Earnings History.

When will Mylan N.V. make its next earnings announcement?

Mylan N.V. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Mylan N.V..

What guidance has Mylan N.V. issued on next quarter's earnings?

Mylan N.V. updated its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share (EPS) guidance of $4.30-4.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.12. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $12.46 billion.

Where is Mylan N.V.'s stock going? Where will Mylan N.V.'s stock price be in 2017?

18 brokers have issued 1-year price objectives for Mylan N.V.'s shares. Their forecasts range from $29.39 to $60.00. On average, they anticipate Mylan N.V.'s share price to reach $43.27 in the next year. View Analyst Ratings for Mylan N.V..

What are analysts saying about Mylan N.V. stock?

Here are some recent quotes from research analysts about Mylan N.V. stock:

  • 1. Argus analysts commented, "junior version" (8/22/2017)
  • 2. According to Zacks Investment Research, "Mylan expects new product launches in the generics segment will propel the top-line. The FDA Oncologic Drugs Advisory Committee (ODAC) recently unanimously recommended approval of Mylan's biosimilar version of breast cancer drug Herceptin. Shares of Mylan have performed better than the industry so far in 2017. However, EpiPen woes continue as sales declined due to increased competition and entry of generics should impact sales. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year. In addition, Mylan received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus. In Apr 2017, Mylan received a warning letter from the FDA for its manufacturing facility in India. The FDA cited significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in the warning letter." (8/1/2017)
  • 3. Mizuho analysts commented, "We were previously modeling 2017 generic Advair sales of $150M ramping to peak sales of $363M in 2020. Without the 2017 contribution we would still fall generally in line with consensus revenue estimates for 2017 (~$12.7B), which is below the mid-point of the guidance range of $12.25-13.75B. It is unclear if Mylan can get its product to the market before year end so it may be more conservative to exclude it for now, though we continue to anticipate its launch next year. While the limited visibility provided on this product may be frustrating to investors, we think that the magnitude of the stock reaction creates a buying opportunity given the small overall contribution from this generic in the near-term. We therefore reiterate our Buy rating and $53 PT. Next Advair-related event: Hikma/Vectura has a May 10 GDUFA date for their own generic Advair, and Hikma indicated that it will be ready to launch immediately after approval. Unlike Mylan’s product, which is hoped to be an AB-rated generic, but also one with brand recognition, Hikma’s generic will not be marketed under a brand name. Hikma mgmt has indicated that its Advair generic will make up the majority of its $120M new-launch guidance in 2017 (assuming one other competitor in the market)." (3/30/2017)
  • 4. Royal Bank Of Canada analysts commented, "MYL reported 4Q today and hosted what we thought was an upbeat 2017 Investor Day showcasing an impressive pipeline. While overall performance remains stable avoiding headwinds felt by smaller peers, 2017 EPS and stock upside will be linked to a few key approvals along with business development. No change to Sector Perform rating but our price target moves up to $48 on higher EPS...First time 2017 guidance was favorable but there are a lot of moving parts to consider. We said going in that an ambitious 2017 outlook wouldn't be enough unless it came with a solid 4Q result. While visibility into specific 4Q drivers was not as high as we would like, it did provide some comfort around MYL's overall stability in a challenging generic environment. The 2017 guidance range of $5.15 to $5.55 captured consensus and helped drive the +7% move in the stock today, but focus will now shift to several important drivers to get there. As we suspected, that range includes risk-adjusted generic Advair, generic Copaxone 20/40mg as well as some incremental business development. Epipen profit impact was quantified and the driver of the slight gross margin moderation. Our new forecasts for 2017-19E move higher and are now $5.30, $5.75 and $6.12 (the $6.00 MYL EPS target in 2018E remains). Based on our new 2018 EBITDA, MYL trades at 9.1x EV/EBITDA - above historical pre-2014 levels." (3/2/2017)

Are investors shorting Mylan N.V.?

Mylan N.V. saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 22,672,282 shares, an increase of 9.2% from the August 15th total of 20,762,241 shares. Based on an average trading volume of 5,983,863 shares, the short-interest ratio is presently 3.8 days. Currently, 4.5% of the shares of the company are sold short.

Who are some of Mylan N.V.'s key competitors?

Who owns Mylan N.V. stock?

Mylan N.V.'s stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.57%), Vanguard Group Inc. (6.14%), State Street Corp (3.82%), Pzena Investment Management LLC (2.30%), Franklin Resources Inc. (1.59%) and Migdal Insurance & Financial Holdings Ltd. (1.29%). Company insiders that own Mylan N.V. stock include Anthony Mauro, Heather M Bresch, John D Sheehan, Joseph C Md Maroon, Laboratories Abbott, Mark W Parrish, Melina E Higgins, Rajiv Malik, Robert J Cindrich, Robert J Coury and Wendy Cameron. View Institutional Ownership Trends for Mylan N.V..

Who sold Mylan N.V. stock? Who is selling Mylan N.V. stock?

Mylan N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Franklin Resources Inc., Cibc World Markets Corp, K2 Principal Fund L.P., Bank of New York Mellon Corp, Hodges Capital Management Inc., Menora Mivtachim Holdings LTD. and Locust Wood Capital Advisers LLC. Company insiders that have sold Mylan N.V. stock in the last year include Anthony Mauro, Laboratories Abbott and Rajiv Malik. View Insider Buying and Selling for Mylan N.V..

Who bought Mylan N.V. stock? Who is buying Mylan N.V. stock?

Mylan N.V.'s stock was acquired by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Vanguard Group Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, BlackRock Inc., Schroder Investment Management Group, Teachers Advisors LLC, Clal Insurance Enterprises Holdings Ltd and Prudential Financial Inc.. Company insiders that have bought Mylan N.V. stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron. View Insider Buying and Selling for Mylan N.V..

How do I buy Mylan N.V. stock?

Shares of Mylan N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan N.V.'s stock price today?

One share of Mylan N.V. stock can currently be purchased for approximately $31.39.

MarketBeat Community Rating for Mylan N.V. (NASDAQ MYL)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  538 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  906
MarketBeat's community ratings are surveys of what our community members think about Mylan N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mylan N.V. (NASDAQ:MYL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $43.27 (37.86% upside)

Analysts' Ratings History for Mylan N.V. (NASDAQ:MYL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017Cantor FitzgeraldReiterated RatingHold$34.00LowView Rating Details
8/22/2017ArgusDowngradeBuy -> Hold$47.59 -> $29.39LowView Rating Details
8/20/2017MizuhoReiterated RatingBuy$53.00 -> $37.00LowView Rating Details
8/16/2017Citigroup Inc.UpgradeNeutral -> Buy$36.00 -> $42.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingOutperform$50.00 -> $45.00HighView Rating Details
8/10/2017Royal Bank Of CanadaReiterated RatingSector Perform$33.00 -> $32.00LowView Rating Details
8/9/2017Cowen and CompanyReiterated RatingHold$43.00 -> $30.00MediumView Rating Details
8/9/2017Wells Fargo & CompanySet Price TargetHold$34.50 -> $30.00MediumView Rating Details
8/7/2017Morgan StanleyLower Price TargetEqual -> Equal Weight$52.00 -> $36.00MediumView Rating Details
5/22/2017Barclays PLCUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
4/18/2017Deutsche Bank AGLower Price TargetBuy$52.00 -> $51.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
3/3/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
1/3/2017BTIG ResearchReiterated RatingBuy$55.00N/AView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016J P Morgan Chase & CoSet Price TargetBuy$52.00N/AView Rating Details
10/10/2016Raymond James Financial, Inc.UpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/25/2016Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$60.00N/AView Rating Details
8/24/2016Bank of America CorporationReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Mylan N.V. (NASDAQ:MYL)
Earnings by Quarter for Mylan N.V. (NASDAQ:MYL)
Earnings History by Quarter for Mylan N.V. (NASDAQ MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$1.20N/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$3.00 billion$2.96 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.81 billion$2.72 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.18 billion$3.27 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.22 billion$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan N.V. (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.58 EPS
Next Year EPS Consensus Estimate: $5.12 EPS


Dividend History for Mylan N.V. (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mylan N.V. (NASDAQ:MYL)
Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 71.97%
Insider Trades by Quarter for Mylan N.V. (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)
Insider Trades by Quarter for Mylan N.V. (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mylan N.V. (NASDAQ:MYL)
Latest Headlines for Mylan N.V. (NASDAQ:MYL)
DateHeadline logoCould Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver? - September 20 at 6:39 AM logoMylan Plans to File Application for Revefenacin in Late 2017 - September 20 at 6:39 AM logoTax inversion deals saved US companies $45 million on average: CBO - Reuters - September 19 at 5:57 AM logoTeva: When Bold Action Just Isn't Possible - September 19 at 12:56 AM logoAnalysts’ Recommendations for Mylan in September 2017 - September 19 at 12:56 AM logoWhy Mylan Lowered Its Revenue Guidance for 2017 - September 19 at 12:56 AM logoCould Mylan See a Rise in Net Profit Margins in 2017? - September 19 at 12:56 AM logoTax inversion deals saved U.S. companies $45 mln on average -CBO - September 19 at 12:56 AM logoDPT Labs negotiates two new Foreign Trade Zones in San Antonio - September 16 at 8:59 PM logoMylan unveils generic oral contraceptive - Pittsburgh Business Times - September 16 at 6:46 AM logoMylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin ... - September 15 at 6:33 AM logoMylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets - September 15 at 6:33 AM logoETFs with exposure to Mylan NV : September 14, 2017 - September 15 at 6:33 AM logoMylan Names Dennis Zeleny as Chief Human Relations Officer - September 14 at 8:07 AM logoMylan NV :MYL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 14 at 8:07 AM logo Analysts Anticipate Mylan N.V. (MYL) Will Post Quarterly Sales of $3.09 Billion - September 14 at 5:24 AM logoShort Interest in Mylan N.V. (MYL) Rises By 9.2% - September 14 at 1:46 AM logoTrading Mylan: Look Out for This Key Level - September 13 at 6:52 AM logoZacks: Analysts Expect Mylan N.V. (MYL) Will Post Earnings of $1.20 Per Share - September 12 at 2:34 PM logoFeds want to deny Martin Shkreli bail - September 10 at 7:59 PM logoMylan N.V. (MYL) Stock Rating Upgraded by BidaskClub - September 10 at 8:10 AM logoMylan N.V. (MYL) Stock Rating Reaffirmed by Cantor Fitzgerald - September 8 at 4:26 PM logoUS FDA warns of problems with EpiPen manufacturing plant - Reuters - September 8 at 6:09 AM logoFDA warns of serious manufacturing violations in letter to EpiPen manufacturing facility - September 8 at 6:09 AM logoEpiPen Maker Neglected ‘Hundreds’ of Complaints About Defects - September 8 at 6:09 AM logoFDA says there have been 'hundreds of complaints' about EpiPen misfires, some patient deaths followed - September 8 at 6:09 AM logoU.S. FDA warns of problems with EpiPen manufacturing plant - September 8 at 6:09 AM logo[$$] FDA Warns Pfizer’s Meridian Unit on EpiPen Oversight, Quality Issues - September 8 at 6:09 AM logoMylan N.V. (MYL) Given Consensus Rating of "Hold" by Analysts - September 6 at 11:01 AM logoMylan N.V. (MYL) Downgraded by ValuEngine - September 2 at 8:50 PM logoTeva: A Complete Overview - August 31 at 7:35 AM logoMylan N.V. (MYL) & Parnell Pharmaceuticals Holdings (PARN) Head to Head Contrast - August 29 at 8:40 AM logo$3.09 Billion in Sales Expected for Mylan N.V. (MYL) This Quarter - August 27 at 11:14 AM logoShort Interest in Mylan N.V. (MYL) Declines By 7.5% - August 27 at 4:04 AM logoMylan in deal to help treat tuberculosis in India, South Africa - Pittsburgh Business Times - August 25 at 8:51 AM logoMylan Granted License To Prioritize Access To Deltyba In South Africa, India - August 24 at 9:50 AM logoWhy Have Mylan's (MYL) Shares Lost 19.4% So Far This Year? - August 24 at 9:50 AM logoOtsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries - August 24 at 9:50 AM logoMylan in deal to help treat tuberculosis in India, South Africa - August 24 at 9:50 AM logoImplied Volatility Surging for Mylan (MYL) Stock Options - August 23 at 8:56 AM logoMylan's Stock Is No Longer A Buy According To Analysts At Argus - August 22 at 9:36 AM logoMylan N.V. (MYL) Cut to Hold at Argus - August 22 at 8:30 AM logoNew Hampshire to get $1 million in EpiPen settlement - August 20 at 11:14 AM logoMizuho Reaffirms "Buy" Rating for Mylan N.V. (MYL) - August 20 at 9:42 AM logoMylan Can Focus on New Generics After EpiPen Medicaid Settlement - August 19 at 4:28 AM logoSen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers - August 18 at 1:51 AM logoOhio to share in $465M settlement with EpiPen maker Mylan - August 17 at 8:50 PM logo[$$] In Hikma's generic race, is third place nowhere? - August 17 at 8:50 PM logoMylan (MYL) Signs $465M Settlement with Agreement on Medicaid Rebate Classification for EpiPen Auto-Injector - August 17 at 3:48 PM logoMylan Finalizes Settlement Agreement On EpiPen Auto-Injector - August 17 at 3:48 PM



Mylan N.V. (MYL) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff